<DOC>
	<DOCNO>NCT00677235</DOCNO>
	<brief_summary>The purpose study confirm long-term safety effectiveness FLAIR Endovascular Stent Graft treatment stenoses venous anastomosis ePTFE synthetic arteriovenous ( AV ) access graft .</brief_summary>
	<brief_title>Post-Approval Study FLAIR Endovascular Stent Graft</brief_title>
	<detailed_description>The purpose study compare efficacy data subject randomize treatment percutaneous transluminal angioplasty ( PTA ) FLAIR™ Endovascular Stent Graft versus subject randomize treatment PTA .</detailed_description>
	<criteria>Subject must either male nonpregnant female great equal 21 year age Subject willing comply protocol requirement contact telephone Subject synthetic AV access graft locate arm implant great equal 30 day undergone least one successful dialysis session prior index procedure Angiographic evidence ( per institution 's standard ) available indicate subject stenosis great equal 50 % locate graftvein anastomosis subject 's synthetic AV access graft The target lesion estimate less equal 7 cm length ( angiography ) The entire target lesion locate within 7 cm graftvein anastomosis , verify angiography , approximately 1 cm FLAIR™ Endovascular Stent Graft extend nondiseased vein approximately 1 cm 2 cm FLAIR™ Endovascular Stent Graft extend nondiseased AV graft Full expansion appropriately size angioplasty balloon , operator 's judgment , achieve primary angioplasty Graft diameter deployment site 5 mm 8 mm verify angiography The subject life expectancy &lt; 25 month . The target lesion correspond thrombosis treat less equal 7 day prior index procedure . A previously place stent and/or stent graft locate treatment area present . Treatment area include entire target lesion 1 cm land zone nondiseased AV graft nondiseased vein . The subject infect AV access graft uncontrolled systemic infection . The presence additional lesion ( ) access circuit less equal 3 cm edge target lesion treat less equal 30 day prior index procedure . The presence additional lesion ( ) access circuit &gt; 3 cm edge primary lesion great equal 30 % stenosed . Note : Subjects may include additional lesion ( ) successfully treat final residual stenosis &lt; 30 % prior index procedure . The location target lesion would require FLAIR™ Endovascular Stent Graft deploy fully across elbow joint ( radiographically identify combination humeroulnar joint humeroradial joint ) . The location target lesion would require FLAIR™ Endovascular Stent Graft cross angle ( inflow vein synthetic AV access graft ) &gt; 90 degree . The subject uncontrolled blood coagulation disorder . The subject know allergy sensitivity contrast medium adequately premedicated . The subject know hypersensitivity nickeltitanium . Subjects currently enrol plan enroll investigation conflict followup test confounds data trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Vascular Prosthesis</keyword>
	<keyword>Stenosis</keyword>
	<keyword>End-stage Renal Disease ( ESRD )</keyword>
</DOC>